GRAIL Announces Availability of Methylation-Based Cell-Free DNA Technology for Research Use Only by Biopharmaceutical Companies; Tech Intended to Accelerate Cancer Research in Post-Diagnostic Setting

On January 9, 2023, GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced the availability of a state-of-the-art research use only offering for biopharmaceutical companies. The new technology solution uses GRAIL’s proprietary targeted methylation platform to analyze cell-free DNA (cfDNA) isolated from peripheral blood for cancer signal interrogation. Potential research use cases include, but are not limited to, prognosis, minimal residual disease detection, and recurrence monitoring across different cancer types in research studies. “GRAIL’s unique methylation technology and bioinformatics capabilities are well suited for circulating tumor DNA analysis across the cancer continuum,” said Bob Ragusa, MS, MBA, Chief Executive Officer at GRAIL. “We are excited to further leverage our methylation platform and introduce our RUO technology solution for cancer prognosis, minimal residual disease detection, recurrence monitoring, and biomarker discovery. The new technology solution has the versatility to be used in solid tumor research and can be customized to improve performance in specific use cases, including custom classifier development.”